首页> 美国卫生研究院文献>Chemical Science >Targeting virulence: salmochelin modification tunes the antibacterial activity spectrum of β-lactams for pathogen-selective killing of Escherichia coli
【2h】

Targeting virulence: salmochelin modification tunes the antibacterial activity spectrum of β-lactams for pathogen-selective killing of Escherichia coli

机译:靶向毒力:沙门菌素修饰可调节β-内酰胺类药物对大肠杆菌的病原体选择性杀灭的抗菌谱

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

New antibiotics are required to treat bacterial infections and counteract the emergence of antibiotic resistance. Pathogen-specific antibiotics have several advantages over broad-spectrum drugs, which include minimal perturbation to the commensal microbiota. We present a strategy for targeting antibiotics to bacterial pathogens that utilises the salmochelin-mediated iron uptake machinery of Gram-negative Escherichia coli. Salmochelins are C-glucosylated derivatives of the siderophore enterobactin. The biosynthesis and utilisation of salmochelins are important for virulence because these siderophores allow pathogens to acquire iron and evade the enterobactin-scavenging host-defense protein lipocalin-2. Inspired by the salmochelins, we report the design and chemoenzymatic preparation of glucosylated enterobactin–β-lactam conjugates that harbour the antibiotics ampicillin (Amp) and amoxicillin (Amx), hereafter GlcEnt–Amp/Amx. The GlcEnt scaffolds are based on mono- and diglucosylated Ent where one catechol moiety is functionalized at the C5 position for antibiotic attachment. We demonstrate that GlcEnt–Amp/Amx provide up to 1000-fold enhanced antimicrobial activity against uropathogenic E. coli relative to the parent β-lactams. Moreover, GlcEnt–Amp/Amx based on a diglucosylated Ent (DGE) platform selectively kill uropathogenic E. coli that express the salmochelin receptor IroN in the presence of non-pathogenic E. coli and other bacterial strains that include the commensal microbe Lactobacillus rhamnosus GG. Moreover, GlcEnt–Amp/Amx evade the host-defense protein lipocalin-2, and exhibit low toxicity to mammalian cells. Our work establishes that siderophore–antibiotic conjugates provide a strategy for targeting virulence, narrowing the activity spectrum of antibiotics in clinical use, and achieving selective delivery of antibacterial cargos to pathogenic bacteria on the basis of siderophore receptor expression.
机译:需要新的抗生素来治疗细菌感染并抵消抗生素耐药性的出现。病原体特异性抗生素与广谱药物相比具有多个优势,其中包括对共生菌群的干扰最小。我们提出了一种针对细菌病原体的抗生素靶向策略,该策略利用了沙门氏菌介导的革兰氏阴性大肠杆菌的铁摄取机制。 Salmochelins是铁载体肠细菌素的C-葡萄糖基化衍生物。 salmochelins的生物合成和利用对于毒力很重要,因为这些铁载体使病原体获得铁并逃避清除肠杆菌素的宿主防御蛋白lipocalin-2。受salmochelins的启发,我们报道了糖基化肠杆菌素-β-内酰胺结合物的设计和化学酶法制备,其中包含了氨苄青霉素(Amp)和阿莫西林(Amx),以下简称为GlcEnt-Amp / Amx。 GlcEnt支架基于单糖基化和二糖基化的Ent,其中一个邻苯二酚部分在C5位置被官能化以附着抗生素。我们证明,相对于母体β-内酰胺类,GlcEnt–Amp / Amx对尿路致病性大肠杆菌提供高达1000倍的增强抗菌活性。此外,基于二糖基化的Ent(DGE)平台的GlcEnt-Amp / Amx在存在非致病性大肠杆菌和其他细菌菌株(包括共生微生物鼠李糖乳杆菌GG)的情况下,选择性杀死表达salmochelin受体IroN的尿路致病性大肠杆菌。 。此外,GlcEnt–Amp / Amx逃避了宿主防御蛋白lipocalin-2,对哺乳动物细胞的毒性低。我们的工作建立了铁载体-抗生素结合物提供了一种针对毒力的策略,在临床使用中缩小了抗生素的活性谱,并在铁载体受体的表达基础上实现了向病原菌选择性递送抗菌药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号